{
  "report_rows": [
    {
      "kpi": "Q2 2026 adjusted EBITDA",
      "prediction": "MISS",
      "answer": "pred ~$315M vs. cons $325M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 net sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.90B vs. cons $3.92B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EPS",
      "prediction": "MISS",
      "answer": "pred ~$1.21 vs. cons $1.29",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted EBITDA",
      "prediction": "LOWER",
      "answer": "guide ~$1.18B vs. cons $1.217B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 net sales",
      "prediction": "LOWER",
      "answer": "guide ~$14.70B vs. cons $14.817B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 free cash flow",
      "prediction": "LOWER",
      "answer": "guide ~$400M vs. cons $480M (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -6.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -8.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FY2026 adjusted EBITDA guidance of ~$1.18B vs. $1.217B consensus and free-cash-flow guidance of ~$400M vs. $480M consensus imply lower second-half margins and estimate revisions, extending the day-1 residual decline from ~-6.0% to ~-8.0% cumulatively by day 5.",
  "day5_confidence": "MEDIUM"
}